Quantcast

Latest Intelliject Inc. Stories

2011-08-01 10:33:00

RICHMOND, Va., Aug. 1, 2011 /PRNewswire/ -- Intelliject, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the company's New Drug Application (NDA) for a novel epinephrine auto-injector, e-cue(TM), for emergency treatment of allergic reactions including anaphylaxis. The tentative approval of e-cue(TM) following a first cycle, 10-month review by the FDA provides validation of Intelliject's vision of developing patient-centric products...

2009-11-30 07:30:00

RICHMOND, Va., Nov. 30 /PRNewswire/ -- Intelliject, Inc. today announced an exclusive license with sanofi-aventis U.S. for a novel epinephrine auto-injector, in the U.S. and Canada territory. Under the license, sanofi-aventis U.S. shall be responsible for manufacturing and commercialization. Intelliject will be responsible for the on-going development and for obtaining U.S. regulatory approval and has retained certain co-promotion rights in the territory. Sanofi-aventis U.S. will pay an...

2009-11-30 07:30:00

BRIDGEWATER, N.J., Nov. 30 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S. and Canada). "We are pleased to have this opportunity to offer this innovative delivery device for the millions of people who are at risk of this life-threatening allergic reaction each year," stated Brent...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related